WEE1 and cancer: Identifications of the roles of abnormal kinase activities in cancer have promoted the development of protein kinase inhibitors such as ST1571 (Gleevec; Druker et al, 1996) and ZD-1839 (Iressa; Ciardiello et al, 2000) as therapeutics.